Comparing Prenetics Global (NASDAQ:PRE) & Nanophase Technologies (OTCMKTS:NANX)

Nanophase Technologies (OTCMKTS:NANX) and Prenetics Global (NASDAQ:PRE) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Valuation & Earnings

This table compares Nanophase Technologies and Prenetics Global”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanophase Technologies	$37.30 million	0.00	-$4.39 million	$0.05	N/A
Prenetics Global	$92.39 million	4.70	-$37.71 million	($4.16)	-6.19

Nanophase Technologies has higher earnings, but lower revenue than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than Nanophase Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nanophase Technologies and Prenetics Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanophase Technologies	5.59%	31.49%	6.67%
Prenetics Global	-47.43%	-21.41%	-15.56%

Volatility and Risk

Nanophase Technologies has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Prenetics Global has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500.

Insider and Institutional Ownership

70.2% of Nanophase Technologies shares are owned by institutional investors. Comparatively, 25.0% of Prenetics Global shares are owned by institutional investors. 5.1% of Nanophase Technologies shares are owned by company insiders. Comparatively, 7.8% of Prenetics Global shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Nanophase Technologies and Prenetics Global, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanophase Technologies	0	0	0	0	0.00
Prenetics Global	1	0	5	0	2.67

Prenetics Global has a consensus price target of $34.80, suggesting a potential upside of 35.09%. Given Prenetics Global’s stronger consensus rating and higher probable upside, analysts clearly believe Prenetics Global is more favorable than Nanophase Technologies.

Summary

Nanophase Technologies beats Prenetics Global on 8 of the 13 factors compared between the two stocks.

About Nanophase Technologies

Nanophase Technologies Corporation, a science-driven company, develops, manufactures, and sells integrated family of nanomaterial technologies in the United States. It engages in engineered materials, formulation development, and commercial manufacturing. The company produces engineered nanomaterial products comprising antimony, bismuth, cerium, iron, and zinc oxide for use in a various markets, including surface finishing,exterior coatings, personal care, plastics, scratch resistant coatings, and textiles. It also provides skin care formulations with mineral-based UV protection under the under the Solésence brand; and advanced material products, including architectural coatings, industrial coatings, abrasion-resistant additives, plastics additives, medical diagnostics, and surface finishing technologies applications. The company was incorporated in 1989 and is headquartered in Romeoville, Illinois.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.